Symbols / NTLA $13.15 -0.45%
NTLA Chart
About
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.55B |
| Enterprise Value | 1.20B | Income | -412.69M | Sales | 67.67M |
| Book/sh | 5.77 | Cash/sh | 3.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | 377 | IPO | — |
| P/E | — | Forward P/E | -4.50 | PEG | — |
| P/S | 22.96 | P/B | 2.28 | P/C | — |
| EV/EBITDA | -2.78 | EV/Sales | 17.69 | Quick Ratio | 4.42 |
| Current Ratio | 5.08 | Debt/Eq | 13.90 | LT Debt/Eq | — |
| EPS (ttm) | -3.81 | EPS next Y | -2.92 | EPS Growth | — |
| Revenue Growth | 78.80% | Earnings | 2026-05-07 | ROA | -27.11% |
| ROE | -53.48% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -4.29% | Profit Margin | 0.00% | Shs Outstand | 118.13M |
| Shs Float | 111.92M | Short Float | 41.98% | Short Ratio | 10.75 |
| Short Interest | — | 52W High | 28.25 | 52W Low | 5.90 |
| Beta | 2.02 | Avg Volume | 4.75M | Volume | 2.73M |
| Target Price | $25.29 | Recom | Buy | Prev Close | $13.21 |
| Price | $13.15 | Change | -0.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.29
Mean price target
2. Current target
$13.15
Latest analyst target
3. DCF / Fair value
$-35.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.15
Low
$5.00
High
$106.00
Mean
$25.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | up | Jones Trading | Hold → Buy | $29 |
| 2026-03-03 | main | Canaccord Genuity | Buy → Buy | $48 |
| 2026-03-03 | main | Leerink Partners | Outperform → Outperform | $29 |
| 2026-03-03 | main | RBC Capital | Sector Perform → Sector Perform | $15 |
| 2026-03-03 | main | Wells Fargo | Equal-Weight → Equal-Weight | $15 |
| 2026-03-03 | main | Citizens | Market Outperform → Market Outperform | $28 |
| 2026-03-03 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-03-02 | main | Chardan Capital | Buy → Buy | $27 |
| 2026-02-27 | main | Chardan Capital | Buy → Buy | $26 |
| 2026-01-28 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-12 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-11-11 | down | Jones Trading | Buy → Hold | — |
| 2025-11-11 | down | Evercore ISI Group | Outperform → In-Line | $8 |
| 2025-11-10 | reit | Truist Securities | Buy → Buy | $14 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-11-07 | main | Chardan Capital | Buy → Buy | $26 |
| 2025-11-07 | main | RBC Capital | Sector Perform → Sector Perform | $9 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $12 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $14 |
| 2025-11-07 | main | Wedbush | Neutral → Neutral | $7 |
- Why did NTLA stock jump 10% in pre-market today? - MSN Wed, 18 Mar 2026 16
- FDA ends trial halt on 1,200-patient heart disease study - Stock Titan Mon, 02 Mar 2026 08
- Why Did NTLA Stock Jump 10% Today? - Stocktwits Mon, 02 Mar 2026 08
- 2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - The Motley Fool Mon, 29 Dec 2025 08
- NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Yahoo Finance Wed, 28 Jan 2026 08
- Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat Mon, 16 Mar 2026 10
- How to watch Intellia’s March investor talks at three healthcare conferences - Stock Titan ue, 24 Feb 2026 08
- Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results - Yahoo Finance Fri, 27 Feb 2026 08
- Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat Mon, 16 Mar 2026 10
- This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - The Motley Fool Sun, 08 Mar 2026 08
- Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
- Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan ue, 03 Mar 2026 08
- HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat Wed, 04 Mar 2026 08
- CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan Fri, 06 Mar 2026 08
- Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? - Yahoo Finance Fri, 14 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1211 | 16688.0 | — | Sale at price 13.78 per share. | BASTA JAMES EDMUND | General Counsel | — | 2026-03-02 00:00:00 | D |
| 1 | 607 | 8364.0 | — | Sale at price 13.78 per share. | CLARK ELIANA | Chief Technology Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 156400 | — | — | Stock Award(Grant) at price 0.00 per share. | LEONARD JOHN M | Chief Executive Officer | — | 2026-02-27 00:00:00 | D |
| 3 | 46080 | — | — | Stock Award(Grant) at price 0.00 per share. | BASTA JAMES EDMUND | General Counsel | — | 2026-02-27 00:00:00 | D |
| 4 | 9943 | — | — | Stock Award(Grant) at price 0.00 per share. | LEBWOHL DAVID | Officer | — | 2026-02-27 00:00:00 | D |
| 5 | 61280 | — | — | Stock Award(Grant) at price 0.00 per share. | DULAC EDWARD J III | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 6 | 7353 | — | — | Stock Award(Grant) at price 0.00 per share. | CLARK ELIANA | Chief Technology Officer | — | 2026-02-27 00:00:00 | D |
| 7 | 17250 | — | — | Stock Award(Grant) at price 0.00 per share. | DUBE MICHAEL P | Officer | — | 2026-02-27 00:00:00 | D |
| 8 | 39200 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHULTES BIRGIT C PH.D. | Officer | — | 2026-02-27 00:00:00 | D |
| 9 | 150000 | 1402500.0 | — | Purchase at price 9.35 per share. | COHEN FREDERICK E. M.D. PH.D. | Director | — | 2026-01-05 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -424.17M | -491.41M | -506.21M | -437.11M |
| TotalUnusualItems | -899.00K | -32.56M | -100.00K | -13.48M |
| TotalUnusualItemsExcludingGoodwill | -899.00K | -32.56M | -100.00K | -13.48M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -412.69M | -519.02M | -481.19M | -474.19M |
| ReconciledDepreciation | 15.92M | 10.29M | 8.98M | 7.57M |
| EBITDA | -425.07M | -523.98M | -506.31M | -450.59M |
| EBIT | -440.99M | -534.26M | -515.29M | -458.16M |
| NetInterestIncome | 29.20M | 47.81M | 49.83M | 8.54M |
| InterestIncome | 29.20M | 47.81M | 49.83M | 8.54M |
| NormalizedIncome | -411.80M | -486.46M | -481.09M | -460.70M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -412.69M | -519.02M | -481.19M | -474.19M |
| TotalExpenses | 508.66M | 592.14M | 551.57M | 510.29M |
| TotalOperatingIncomeAsReported | -440.99M | -534.26M | -515.29M | -458.16M |
| DilutedAverageShares | 108.38M | 98.85M | 88.77M | 76.97M |
| BasicAverageShares | 108.38M | 98.85M | 88.77M | 76.97M |
| DilutedEPS | -3.81 | -5.25 | -5.42 | -6.16 |
| BasicEPS | -3.81 | -5.25 | -5.42 | -6.16 |
| DilutedNIAvailtoComStockholders | -412.69M | -519.02M | -481.19M | -474.19M |
| NetIncomeCommonStockholders | -412.69M | -519.02M | -481.19M | -474.19M |
| NetIncome | -412.69M | -519.02M | -481.19M | -474.19M |
| NetIncomeIncludingNoncontrollingInterests | -412.69M | -519.02M | -481.19M | -474.19M |
| NetIncomeContinuousOperations | -412.69M | -519.02M | -481.19M | -474.19M |
| PretaxIncome | -412.69M | -519.02M | -481.19M | -474.19M |
| OtherIncomeExpense | -899.00K | -32.56M | -15.73M | -24.56M |
| SpecialIncomeCharges | 0.00 | 0.00 | -100.00K | -13.48M |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | 100.00K | 13.48M |
| EarningsFromEquityInterest | 0.00 | 0.00 | -15.63M | -11.08M |
| GainOnSaleOfSecurity | -899.00K | -32.56M | ||
| NetNonOperatingInterestIncomeExpense | 29.20M | 47.81M | 49.83M | 8.54M |
| InterestIncomeNonOperating | 29.20M | 47.81M | 49.83M | 8.54M |
| OperatingIncome | -440.99M | -534.26M | -515.29M | -458.16M |
| OperatingExpense | 508.66M | 592.14M | 551.57M | 510.29M |
| ResearchAndDevelopment | 388.86M | 466.31M | 435.07M | 419.98M |
| SellingGeneralAndAdministration | 119.80M | 125.83M | 116.50M | 90.31M |
| GeneralAndAdministrativeExpense | 119.80M | 125.83M | 116.50M | 90.31M |
| OtherGandA | 119.80M | 125.83M | 116.50M | 90.31M |
| TotalRevenue | 67.67M | 57.88M | 36.27M | 52.12M |
| OperatingRevenue | 67.67M | 57.88M | 36.27M | 52.12M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 116.32M | 102.03M | 93.00M | 87.10M |
| ShareIssued | 116.32M | 102.03M | 93.00M | 87.10M |
| TotalDebt | 93.33M | 210.20M | 115.35M | 130.70M |
| TangibleBookValue | 671.39M | 871.96M | 1.05B | 1.24B |
| InvestedCapital | 671.39M | 871.96M | 1.05B | 1.24B |
| WorkingCapital | 423.83M | 529.01M | 883.12M | 1.09B |
| NetTangibleAssets | 671.39M | 871.96M | 1.05B | 1.24B |
| CapitalLeaseObligations | 93.33M | 210.20M | 115.35M | 130.70M |
| CommonStockEquity | 671.39M | 871.96M | 1.05B | 1.24B |
| TotalCapitalization | 671.39M | 871.96M | 1.05B | 1.24B |
| TotalEquityGrossMinorityInterest | 671.39M | 871.96M | 1.05B | 1.24B |
| StockholdersEquity | 671.39M | 871.96M | 1.05B | 1.24B |
| GainsLossesNotAffectingRetainedEarnings | 1.03M | 605.00K | -2.26M | -7.46M |
| OtherEquityAdjustments | 1.03M | 605.00K | -2.26M | -7.46M |
| RetainedEarnings | -2.59B | -2.18B | -1.66B | -1.18B |
| AdditionalPaidInCapital | 3.26B | 3.05B | 2.71B | 2.42B |
| CapitalStock | 12.00K | 10.00K | 9.00K | 9.00K |
| CommonStock | 12.00K | 10.00K | 9.00K | 9.00K |
| TotalLiabilitiesNetMinorityInterest | 170.73M | 319.06M | 250.81M | 284.53M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 66.85M | 208.21M | 135.60M | 157.98M |
| OtherNonCurrentLiabilities | 24.03M | |||
| NonCurrentDeferredLiabilities | 0.00 | 18.26M | 38.85M | 19.93M |
| NonCurrentDeferredRevenue | 0.00 | 18.26M | 38.85M | 19.93M |
| LongTermDebtAndCapitalLeaseObligation | 66.85M | 189.95M | 96.75M | 114.02M |
| LongTermCapitalLeaseObligation | 66.85M | 189.95M | 96.75M | 114.02M |
| CurrentLiabilities | 103.88M | 110.85M | 115.21M | 126.55M |
| CurrentDeferredLiabilities | 7.29M | 20.66M | 22.14M | 43.84M |
| CurrentDeferredRevenue | 7.29M | 20.66M | 22.14M | 43.84M |
| CurrentDebtAndCapitalLeaseObligation | 26.48M | 20.25M | 18.60M | 16.68M |
| CurrentCapitalLeaseObligation | 26.48M | 20.25M | 18.60M | 16.68M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 23.07M | 24.07M | 26.61M | 21.78M |
| PayablesAndAccruedExpenses | 47.04M | 45.87M | 47.85M | 44.25M |
| CurrentAccruedExpenses | 26.79M | 31.28M | 40.40M | 39.10M |
| Payables | 20.25M | 14.59M | 7.45M | 5.15M |
| AccountsPayable | 20.25M | 14.59M | 7.45M | 5.15M |
| TotalAssets | 842.13M | 1.19B | 1.30B | 1.52B |
| TotalNonCurrentAssets | 314.42M | 551.15M | 302.65M | 303.32M |
| InvestmentsAndAdvances | 190.79M | 304.48M | 154.51M | 142.32M |
| OtherInvestments | 35.54M | 44.26M | 42.88M | 40.53M |
| InvestmentinFinancialAssets | 155.25M | 260.21M | 99.86M | 69.34M |
| AvailableForSaleSecurities | 155.25M | 260.21M | 99.86M | 69.34M |
| LongTermEquityInvestment | 0.00 | 11.77M | 32.45M | 58.13M |
| NetPPE | 123.63M | 246.67M | 148.13M | 161.00M |
| AccumulatedDepreciation | -58.61M | -49.69M | -39.86M | -33.20M |
| GrossPPE | 182.23M | 296.36M | 188.00M | 194.20M |
| Leases | 3.20M | 3.20M | 3.13M | 3.07M |
| OtherProperties | 173.82M | 287.65M | 179.34M | 184.99M |
| MachineryFurnitureEquipment | 5.21M | 5.52M | 5.52M | 6.14M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 527.71M | 639.86M | 998.33M | 1.22B |
| OtherCurrentAssets | 68.36M | 29.83M | 49.65M | 20.41M |
| PrepaidAssets | 18.58M | |||
| Receivables | 9.47M | 8.52M | 36.46M | 3.77M |
| AccountsReceivable | 9.47M | 8.52M | 36.46M | 3.77M |
| CashCashEquivalentsAndShortTermInvestments | 449.88M | 601.51M | 912.22M | 1.19B |
| OtherShortTermInvestments | 294.42M | 412.33M | 685.48M | 669.12M |
| CashAndCashEquivalents | 155.46M | 189.18M | 226.75M | 523.51M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -395.87M | -354.66M | -408.07M | -391.68M |
| IssuanceOfCapitalStock | 128.18M | 176.90M | 119.80M | 565.79M |
| CapitalExpenditure | -1.13M | -5.78M | -13.98M | -58.39M |
| EndCashPosition | 167.57M | 202.79M | 240.35M | 535.46M |
| BeginningCashPosition | 202.79M | 240.35M | 535.46M | 125.49M |
| ChangesInCash | -35.22M | -37.57M | -295.11M | 409.98M |
| FinancingCashFlow | 131.49M | 185.75M | 130.32M | 582.96M |
| CashFlowFromContinuingFinancingActivities | 131.49M | 185.75M | 130.32M | 582.96M |
| ProceedsFromStockOptionExercised | 3.31M | 8.85M | 10.53M | 17.17M |
| NetCommonStockIssuance | 128.18M | 176.90M | 119.80M | 565.79M |
| CommonStockIssuance | 128.18M | 176.90M | 119.80M | 565.79M |
| InvestingCashFlow | 228.03M | 125.57M | -31.35M | 160.31M |
| CashFlowFromContinuingInvestingActivities | 228.03M | 125.57M | -31.35M | 160.31M |
| NetInvestmentPurchaseAndSale | 229.16M | 131.34M | -17.36M | 218.55M |
| SaleOfInvestment | 551.67M | 1.07B | 887.10M | 647.58M |
| PurchaseOfInvestment | -322.51M | -935.57M | -904.46M | -429.03M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -3.00M | |
| PurchaseOfBusiness | 0.00 | 0.00 | -3.00M | |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -44.83M | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -44.83M | 0.00 |
| NetPPEPurchaseAndSale | -1.13M | -5.78M | -13.98M | -13.41M |
| SaleOfPPE | 0.00 | 0.00 | 150.00K | 0.00 |
| PurchaseOfPPE | -1.13M | -5.78M | -13.98M | -13.56M |
| OperatingCashFlow | -394.74M | -348.88M | -394.09M | -333.29M |
| CashFlowFromContinuingOperatingActivities | -394.74M | -348.88M | -394.09M | -333.29M |
| ChangeInWorkingCapital | -73.75M | 11.88M | -52.45M | -53.87M |
| ChangeInOtherWorkingCapital | -28.11M | -22.08M | -2.78M | -63.46M |
| ChangeInOtherCurrentLiabilities | -54.95M | -17.97M | -16.67M | -9.88M |
| ChangeInOtherCurrentAssets | 35.90M | 22.38M | 18.30M | 12.03M |
| ChangeInPayablesAndAccruedExpense | 716.00K | -3.58M | 8.55M | 11.34M |
| ChangeInAccruedExpense | -5.27M | -10.38M | 6.02M | 15.92M |
| ChangeInPayable | 5.99M | 6.80M | 2.52M | -4.58M |
| ChangeInAccountPayable | 5.99M | 6.80M | 2.52M | -4.58M |
| ChangeInPrepaidAssets | -26.35M | 5.18M | -27.17M | -2.16M |
| ChangeInReceivables | -951.00K | 27.94M | -32.69M | -1.74M |
| ChangesInAccountReceivables | -951.00K | 27.94M | -32.69M | -1.74M |
| OtherNonCashItems | -20.97M | 6.72M | 80.88M | 2.94M |
| StockBasedCompensation | 80.22M | 154.27M | 134.05M | 91.40M |
| UnrealizedGainLossOnInvestmentSecurities | 899.00K | 32.56M | 0.00 | 0.00 |
| AmortizationOfSecurities | -5.86M | -17.82M | -25.90M | 4.00M |
| DepreciationAmortizationDepletion | 15.92M | 10.29M | 8.98M | 7.57M |
| DepreciationAndAmortization | 15.92M | 10.29M | 8.98M | 7.57M |
| Depreciation | 15.92M | 10.29M | 8.98M | |
| OperatingGainsLosses | 527.00K | -76.00K | 15.71M | 10.92M |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | 15.63M | 11.08M |
| GainLossOnSaleOfPPE | 527.00K | -76.00K | 72.00K | -162.00K |
| NetIncomeFromContinuingOperations | -412.69M | -519.02M | -481.19M | -474.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NTLA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|